InterAx developed a unique drug discovery platform integrating biochemistry, cellular pathways mathematical modelling and AI to decode the cellular communication language. This novel approach enables the rapid and precise identification of differentiated effective and safe candidates.

Products, services, technology

Oral daily GLP-1R agonist (IAX30-series) for T2D and weight loss. It offers an optimal profile to reduce nausea, it enables prevention of T2D progression and holds potential for combination with a GIP-R antagonist (IAX35-series) to maximize weight-loss efficacy with improved tolerability.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2016
  • Number of employees in Switzerland
    10-19
Key business

You may also be interested in